PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: Implications for the therapeutics of schizophrenia

American Journal of Psychiatry

Volumn 154, Issue 11, 1997, Pages 1525-1529

  Kapur, Shitij ^a   Zipursky, Robert ^b   Remington, Gary ^b   Jones, Corey ^b   McKay, Gordon ^b   Houle, Sylvain ^b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; DIBENZOXAZEPINE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; LOXAPINE; NEUROLEPTIC AGENT; RACLOPRIDE; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR; SETOPERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; SCHIZOPHRENIA;

EID: 0030781693     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.154.11.1525     Document Type: Article

References (34)

1. Meltzer HY, Matsubara S, Lee JC: The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25:390-392
2. Meltzer HY, Matsubara S, Lee JC: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2 pKi values. J Pharmacol Exp Ther 1989; 251: 238-246
3. Kapur S, Remington G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153:466-476
4. Meltzer HY: The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J Clin Psychopharmacol 1995; 15:2S-3S
5. Seeman P: Therapeutic receptor-blocking concentrations of neuroleptics. Int Clin Psychopharmacol 1995; 10:5-13
6. Singh AN, Barlas C, Singh S, Franks P, Mishra RK: A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. J Psychiatry Neurosci 1996; 21:1-7
7. Leysen JE, Janssen PM, Schotte A, Luyten WH, Megens AA: Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl) 1993; 112:S40-S54
8. Helmeste DM, Tang SW: Unusual acute effects of antidepressants and neuroleptics on S2-serotonergic receptors. Life Sci 1983; 33:2527-2533
9. Lee T, Tang SW: Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain. Psychiatry Res 1984; 12:277-285
10. Seeman P: Receptor Tables: Drug Dissociation Constants for Neuroreceptors and Transporters, vol 2. Toronto, SZ Research, 1993
11. Kapur S, Zipursky R, Jones C, Remington G, Wilson A, DaSilva J, Houle S: The D2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology 1996; 15:562-566
12. 11C]-raclopride binding using a bolus plus infusion protocol, in Quantification of Brain Function Using PET. Edited by Myers R, Cunningham B, Bailey D, Jones T. San Diego, Academic Press, 1996, pp 262-265
13. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G: Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544
14. Blin J, Pappata S, Kiyosawa M, Crouzel C, Baron JC: [18F]Setoperone: a new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo. Eur J Pharmacol 1988; 147:73-82
15. Blin J, Sette G, Fiorelli M, Bletry O, Elghozi JL, Crouzel C, Baron JC: A method for the in vivo investigation of the serotonergic 5-HT2 receptors in the human cerebral cortex using positron emission tomography and 18F-labeled setoperone. J Neurochem 1990; 54:1744-1754
16. 18F]-setoperone. J Labelled Compounds and Radiopharmaceuticals 1988; 25:403-414
17. Pazos A, Probst A, Palacios JM: Serotonin receptors in the human brain, IV: autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987; 21:123-139
18. Petit-Taboue MC, Landeau B, Osmont A, Tiller I, Barre L, Baron JC: Estimation of neocortical serotonin-2 receptor binding potential by single-dose fluorine-18-setoperone kinetic PET data analysis. J Nucl Med 1996; 37:95-104
19. Mazoyer B: Investigation of the dopamine system with positron emission tomography: general issues in modelling, in Brain Dopaminergic Systems: Imaging With Positron Emission Tomography, vol 20. Edited by Baron J, Comar D, Farde L, Martinot J, Mazoyer B. Dordrecht, the Netherlands, Kluwer Academic, 1991, pp 64-83
20. 18F]-setoperone PET imaging. Nucl Med Commun 1997; 18:395-399
21. Wong DF, Wagner HN Jr, Dannals RF, Links JM, Frost JJ, Ravert HT, Wilson AA, Rosenbaum AE, Gjedde A, Douglass KH: Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984; 226:1393-1396
22. 2 receptor density in schizophrenia (abstract). Biol Psychiatry 1997; 41:63S
23. Okubo Y, Suhara T, Sudo Y, Someya Y, Sassa T, Terasaki O, Suzuki K, Toru M: Dopamine D1, D2 and 5HT2 receptors in schizophrenic patients: a PET study using [11C]-SCH23390 and [11C]-NMSP, in Abstract Book of the Third Pan Pacific Conference on Brain Topography, Tokyo, Japan, 1997, p 18
24. Midha KK, Hubbard JW, McKay G, Hawes EM, Hsia D: The role of metabolites in a bioequivalence study, 1: loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine. Int J Clin Pharmacol Ther Toxicol 1993; 31:177-183
25. Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, Meltzer HY: Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 1993; 266:1374-1384
26. 3H-Spiroperidol binding to dopamine receptors in rat striatal membranes: influence of loxapine and its hydroxylated metabolites. Eur J Pharmacol 1979; 55:215-218
27. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995; 152:1444-1449
28. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van-Gompel P, Lesage AS, DeLoore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124: 57-73
29. Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S: The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995; 57:PL103-PL107
30. Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY: D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl) 1995; 120:365-368
31. Bolanos FJ, Schlechter LE, Miquel MC, Emerit MB, Rumigny JF, Hamon M, Gozlan H: Common pharmacological and physicochemical properties of 5-HT3 binding sites in the rat cerebral cortex and NG 108-15 clonal cells. Biochem Pharmacol 1990; 40:1541-1550
32. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994; 268: 1403-1410
33. Shen Y, Monsma FJ Jr, Metcalf MA, Jose PA, Hamblin MW, Sibley DR: Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem 1993; 268: 18200-18204
34. Kapur S, Zipursky RB, Jones C, Wilson AA, DaSilva JD, Houle S: Cyproheptadine: a potent in vivo serotonin antagonist (letter). Am J Psychiatry 1997; 153:884